BeiGene (HKG:6160, SHA:688235) shareholder Hillhouse Capital reduced their stakes in the cancer drug manufacturer in Hong Kong, according to separate disclosures to the Hong Kong bourse on March 5.

The investment manager, through HHLR Fund and HHLR Advisors, sold 32,240,000 shares at an average price of $18.81 apiece, according to the disclosure.

Hillhouse now holds a 5.70% stake, or 79,357,423 shares, from its 111,597,423 shares, or an 8.01% stake.